logo

Cardiff Oncology, Inc. (CRDF)



Trade CRDF now with
  Date
  Headline
9/8/2021 4:04:28 PM Cardiff Oncology Announces New Data From Phase 1b/2 Trial In KRAS-mutated Metastatic Colorectal Cancer
8/25/2021 8:21:17 AM Cardiff Oncology To Present New Data From Lead Clinical Program In KRAS-mutated Metastatic Colorectal Cancer On Sept 8
7/12/2021 8:03:47 AM Cardiff Oncology Says Appoints James Levine As CFO
6/8/2021 8:37:12 AM Cardiff Oncology Doses First Patient In Phase 2 Trial Of Onvansertib With Irinotecan And 5-FU In Pancreatic Cancer
4/12/2021 6:09:28 AM Cardiff Oncology: Onvansertib Phase 1b/2 Data Continues To Demonstrate Robust Response In KRAS-Mutated MCRC
2/11/2021 8:21:27 AM Cardiff : Phase 2 MCRPC Trial Data Shows Two-Fold Increase In Efficacy With Optimized Onvansertib Dosing Schedule
1/26/2021 8:27:44 AM Cardiff Oncology Gets "Study May Proceed" From FDA To Initiate Phase 2 Trial Of Onvansertib In Metastatic PDAC
1/15/2021 8:19:57 AM Cardiff Oncology Presents Data From Phase 1b/2 Study In KRAS-mutated Metastatic Colorectal Cancer
12/21/2020 4:18:49 PM Cardiff Oncology Appoints Rodney Markin As Chairman Of Board
9/30/2020 12:31:00 AM Cardiff Oncology Reports Pricing Of Public Offering Of 6.5 Mln Shares At $13.50/Shr
9/29/2020 4:03:12 PM Cardiff Oncology Announces Proposed Public Offering